[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"desmoid-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:desmoid-tumor":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,49,70,95,126,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100606525","phase-4-nirogacestat-in-premenopausal-females-with-desmoid-tumoraggressive-fibromatosis-dtaf-100606525",false,"NCT07176689","Nirogacestat in Premenopausal Females With Desmoid Tumor\u002FAggressive Fibromatosis (DT\u002FAF)","A Single-Arm, Open-Label Phase 4 Study of Nirogacestat in Adult Premenopausal Females With Desmoid Tumors\u002FAggressive Fibromatosis (DT\u002FAF)","Inclusion Criteria:\n\n* Participant is female, postpubertal aged ≥18 and ≤40 years of age at the time of signing the informed consent and premenopausal at baseline. Premenopausal is defined as meeting all of the following: Estradiol \\>30 pg\u002FmL. Follicle-stimulating hormone (FSH) \\\u003C40 IU\u002FL. Regular menses (e.g., menstrual cycle length of 21 to 35 days) for at least 3 menstrual cycles prior to signing informed consent\n* Participant uses 1 highly effective non-hormonal contraceptive method, has a negative pregnancy test prior to first dose of study treatment), is not breastfeeding, agrees to not harvest or donate eggs for at least 90 days prior to and during the study\n* Participant has histologically confirmed DT\u002FAF with symptomatic or progressive disease requiring systemic treatment\n* Participant has an Eastern Cooperative Oncology Group (ECOG) performance status ≤2 at screening\n* Participant has adequate organ and bone marrow function.\n\nExclusion Criteria:\n\n* Participant has known malabsorption syndrome or preexisting gastrointestinal conditions that may impair absorption of nirogacestat\n* Participant has experienced any of the following within 6 months of signing informed consent: clinically significant cardiac disease (New York Heart Association Class III or IV), myocardial infarction, severe\u002Funstable angina, coronary\u002Fperipheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, or symptomatic pulmonary embolism.\n* Participant has had lymphoma, leukemia, or any malignancy within the past 5 years at the time of informed consent, except for any locally recurring cancer that has been treated curatively (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast), with no evidence of metastatic disease for 3 years at the time of informed consent.\n* Participant has known hepatic impairment\n* Participant previously received or is currently receiving gamma secretase inhibitors or anti-Notch antibody therapy\n* Participant is currently using any treatment for DT\u002FAF including tyrosine kinase inhibitors (TKIs) or any investigational treatment 28 days (or 5 half-lives, whichever is longer) prior to the first dose of study treatment\n* Participant is currently using or anticipates using food or drugs that are known strong\u002Fmoderate cytochrome P450 (CYP) 3A4 inhibitors, or strong CYP3A inducers within 14 days prior to the first dose of study treatment.\n* Participant has a history of polycystic ovary syndrome, hypothalamic amenorrhea, severe endometriosis involving ovaries, family history of primary ovarian insufficiency, any chromosomal abnormality, mutation, gene variant or medical condition associated with early\u002Fpremature menopause, including a history of OT while on a TKI\n* Participant is currently using or has used hormonal contraception or ovarian suppression within 90 days prior to first dose of study treatment\n* Participant has a history of heavy tobacco smoking (≥20 pack years) or is a current smoker (\\>1 pack per day)\n* Participant has experienced other severe acute or chronic medical or psychiatric conditions within 1 year of signing informed consent.\n* Participant is unable to comply with study related procedures (including, but not limited to, the completion of a menstrual diary and electronic patient-reported outcomes and ability to return to clinic for hormone level blood draws timed to the menstrual cycle (days 1-5)","FEMALE","18 Years","40 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This study is being conducted to study how nirogacestat may affect the ovarian function of adult premenopausal women with progressing desmoid tumors\u002Faggressive fibromatosis.",[27,28],"Desmoid Tumor","Aggressive Fibromatosis",[30,31,32,33,34,35],"Nirogacestat","PF-03084014","GSI","gamma secretase inhibitor","notch pathway","Ogsiveo","RECRUITING","2026-06-17",{"date":39,"type":40},"2026-06-22","ACTUAL",{"date":42,"type":40},"2025-09-17",{"date":44,"type":21},"2031-04-24",{"name":46,"class":47},"SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany","INDUSTRY",23,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":69,"locationsCount":4},"100442411","individual-patient-compassionate-use-of-nirogacestat-100442411","NCT05041036","Individual Patient Compassionate Use of Nirogacestat","Inclusion Criteria:\n\n* Patient has a serious, debilitating or life-threatening medical condition that cannot be treated satisfactorily with an authorized medicinal product or other available standard treatment options, or all other treatment options have been exhausted.\n* Patient does not qualify to participate in an ongoing clinical trial.","ALL","EXPANDED_ACCESS","This program is being offered on a patient by patient basis and will require company, Institutional Review Board\u002FIndependent Ethics Committee, and applicable competent authority approval.",[27,59],"NOTCH Gene Mutation Positive Tumors",[61,62,63,64],"desmoid tumor","aggressive fibromatosis","desmoid fibromatosis","Notch-positive tumors","AVAILABLE","2026-05-04",{"date":68,"type":40},"2026-05-08",{"name":46,"class":47},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100634572","phase-2-a-study-in-adults-with-desmoid-tumors-100634572","NCT07541430","A Study in Adults With Desmoid Tumors","An Open-Label, Multicenter, Single-Arm Phase 2 Study of ES014 in Adult Subjects With Desmoid Tumors","Inclusion Criteria:\n\n* 1\\) Histologically confirmed desmoid tumor.\n* 2)Within 12 months prior to enrollment, meeting any of the following: Tumor target lesion growth ≥ 20% or appearance of new lesions;Desmoid tumor-related pain not adequately controlled by non-opioid medications.\n* 3)Meeting any of the following conditions: Subjects with recurrence or disease progression after at least one line of treatment (including surgery, radiotherapy, or systemic therapy, etc.); Treatment-naive subjects who are deemed suitable for the study drug by the investigator.\n* 4)Presence of at least one measurable lesion (according to RECIST v1.1).\n* 5)Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-2.\n* 6)Life expectancy of at least 12 weeks.\n* 7)Adequate hematologic, hepatic, renal and coagulation functions per protocol.\n* 8)Male and female subjects of childbearing potential must be willing to completely abstain or agree to use a highly effective method of contraception.\n\nExclusion Criteria:\n\n* 1)Any prior therapy targeting CD39, CD73, adenosine A2A receptor, or TGF-β.\n* 2)Receipt of any investigational agents or devices within 4 weeks prior to the first dose of study drug.\n* 3)Prior treatment with any of the following:\n\n  1. Anticancer therapy, including chemotherapy, tyrosine kinase inhibitors (TKIs), etc., within 28 days or 5 half-lives (whichever is shorter, but not less than 14 days) prior to the first dose of study drug.\n  2. For subjects who have received radiotherapy, a washout period of at least 2 weeks (limb radiation) or 4 weeks (chest, brain, or visceral organ radiation) is required before the start of study drug administration.\n  3. Traditional Chinese medicine (TCM) and proprietary Chinese medicines: if the package insert or investigator deems them to have clear anti-tumor effects, a 14-day washout is required. Other TCM and proprietary Chinese medicines do not require a washout.\n* 4)Prior allogeneic or autologous bone marrow transplantation or solid organ transplantation.\n* 5)Previous treatment-related toxicities unresolved to ≤ Grade 1, with the exception of alopecia (any grade), ≤ Grade 2 peripheral sensory neuropathy, and long-standing irreversible toxicities at the investigator's discretion.\n* 6)Major surgery within 4 weeks prior to the first dose of study treatment.\n* 7)Live vaccination therapies within 4 weeks prior to the first dose of study treatment.",{"count":20,"type":21},[79],"PHASE2","This is an open-label, multicenter, single-arm phase 2 clinical study designed to evaluate the efficacy, safety, tolerability, patient-reported outcomes (PROs), pharmacokinetics (PK), anti-drug antibody (ADA) and pharmacodynamics (PD) of ES014 in adult desmoid tumor patients.",[27],[83,84,85],"CD39","TGF-β","CD39xTGF-β","2026-04-26",{"date":88,"type":40},"2026-04-30",{"date":88,"type":21},{"date":91,"type":21},"2028-10",{"name":93,"class":47},"Elpiscience (Suzhou) Biopharma, Ltd.",1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":55,"minAge":103,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":108,"conditions":109,"keywords":110,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":125},"100522344","cryoablation-versus-medical-therapy-in-desmoid-tumors-progressing-after-watchful-waiting-100522344","NCT06081400","Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting","A Phase II Multicentric, Randomized Trial Assessing Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting","CRYODESMO-02","Inclusion Criteria:\n\n* Subject (male or female) with extra-peritoneal desmoid tumor (confirmed by prior biopsy by an experienced pathologist within the RRePS network)\n* 13 years of age or older\n* Measurable viable tumor (according to the mRECIST criteria using MRI. The baseline MRI imaging is mandatory in the 2 months prior to treatment initiation (D0).\n* Progressive disease (according to the mRECIST criteria) after the watchful waiting period or significant increase in symptoms requiring an active therapy, as advised in a multidisciplinary sarcoma tumor board\n* Tumor deemed accessible for cryoablation procedure by the operator in a type I center. (In pediatric cases, a careful site tumor analysis will be performed with interventional radiologist to ensure for limited consequence of cryoablation in pediatric patients especially regarding growth plates).\n* 100 % of destruction of the tumor achievable in one procedure of cryoablation with 1cm security margin according to assessment by referral center (type 1) for cryoablation\n* ECOG performance status 0-2 at inclusion visit\n* Biological and hematological parameters (neutrophils ≥ 1,5.109\u002FL ; platelet count ≥ 100.109\u002FL ; no significant hemostatic abnormalities) in the 4 weeks prior to treatment initiation (D0)\n* Subject able to understand the objectives and risks of the research and to give dated and signed informed consent. For minors, the consent of the 2 parents must be obtained.\n* Subject affiliated to a social health insurance plan\n* For a woman of childbearing age: negative blood pregnancy test at screening\u002Finclusion visit\n* Subject agreeing to use a contraceptive method\n\nExclusion criteria:\n\n* Intra-peritoneal or multifocal desmoid tumor\n* Concurrent or prior use of any antitumor agent for the current desmoid tumor\n* Relapse after surgery for desmoid tumor\n* Any contraindication including known hypersensitivity to vinorelbine or other vinca-alkaloids, or other constituents to navelbine, to vinblastine, to methotrexate or any excipients, such as, but not limited to current or recent (within 2 weeks) severe infection, severe renal failure, severe hepatic injury, chronic respiratory failure\n* Any contraindication including hypersensitivity to gadoteric acid, meglumine or any drug containing gadolinium\n* Concomitant treatment with: yellow fever vaccine, prophylactic treatment with phenytoin, trimethoprim, ciprofloxacin, penicillins, probenecid, acetylsalicylic acid, NSAIDs, PPIs, acitretin, azote protoxide, St John's wort\n* Any contra-indication for the procedure as stated by the interventional radiologist in terms of tumor size, proximity to neural\u002Fvascular structures or adjacent organs at risk making the procedure at unacceptable risk\n* Impaired hemostasis, that may interfere with the conduct of the cryoablation\n* Contraindication to any form of sedation\n* Others contra-indications to MRI\n* Pregnancy or breastfeeding\n* Concurrent participation in other experimental studies that could affect endpoints of the present study\n* Impossibility to give the subject informed information (subject in an emergency situation, patient with comprehension difficulties ...)\n* Psychiatric disorders\n* Incompetent subject (subject to a legal protection measure: curatorship, guardianship, future protection mandate, family habilitation)","13 Years",{"count":105,"type":21},150,[107],"NA","\"Wait \\& see\" is currently the standard of care of recently diagnosed desmoid tumors (DT). In case of progression or symptomatic disease, medical therapy is nowadays widely used including chemotherapy.\n\nCryoablation has proven to be beneficial for the treatment of large, progressive and symptomatic DT.\n\nThis randomized phase II trial aims to compare cryoablation versus medical therapy in DT patients progressing after the \"wait \\& see\" period. Moreover, a cross-over design has been anticipated to allow all patients to undergo cryoablation if necessary.",[27],[111,112,113,114],"Desmoids","Cryoablation","Drug therapy","Cross-Over Studies","2025-11-14",{"date":117,"type":40},"2025-11-19",{"date":119,"type":40},"2024-03-04",{"date":121,"type":21},"2029-06",{"name":123,"class":124},"University Hospital, Strasbourg, France","OTHER",13,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":138,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":94},"100512180","phase-2-study-of-cryoablation-and-nirogacestat-for-desmoid-tumor-100512180","NCT05949099","Study of Cryoablation and Nirogacestat for Desmoid Tumor","Phase II Study of Cryoablation and Nirogacestat for Desmoid Tumor","Inclusion Criteria:\n\n1. Histologically-confirmed diagnosis of desmoid tumor (DT) that is progressing (by RECIST criteria over the past 12 months) or symptomatic (as defined by change in pain regimen or impairment of activities of daily living (ADLs), or at investigator discretion). Note: Must have diagnosis of desmoid tumor on pathology report.\n2. Desmoid tumor is 50 to \\\u003C75% cryoablatable.\n\n   Tumors that are 50 to \\\u003C75% (volume) ablatable in a single session are characterized by:\n   1. Proximity (\\\u003C 1 cm) to critical structures, such as nerves, vessels, bowel, or skin, at risk of injury during ablation, despite hydrodissection\n   2. Large size ( \\> 100 mL)\n   3. Complex shape, such that parts of the tumor cannot be reached from a single approach or subject position\n   4. Thin, infiltrative components, where ablation of that portion would damage more normal anatomy than tumor (e.g., tumor extending along a fascial plane between muscles, such that ablation would damage more muscle than tumor volume)\n3. If participant is currently being treated with any therapy for the treatment of DT, this must be completed at least 28 days (or 5 half-lives, whichever is shorter) prior to first dose of study treatment. All toxicities from prior therapy must be resolved to ≤ Grade 1 or clinical baseline.\n4. Participants who are receiving chronic nonsteroidal anti-inflammatory drugs (NSAIDs) as treatment for conditions other than DT must be on a stable dose for at least 28 days prior to first dose of study treatment.\n5. Age ≥ 18 years.\n6. Participant has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 at screening.\n7. Participant has adequate organ and bone marrow function as defined by the following screening laboratory values:\n\n   1. Absolute neutrophil count ≥ 1500 cells\u002FμL;\n   2. Platelets ≥ 100,000μL;\n   3. Hemoglobin ≥ 9 g\u002FdL;\n   4. Total bilirubin ≤ 1.5 × upper limit of normal (ULN) (isolated bilirubin \\> 1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin \\\u003C 35%);\n   5. Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase)\u002Falanine aminotransferase (ALT) (serum glutamic pyruvate transaminase) ≤ 2 × ULN; and\n   6. Serum creatinine ≤ 1.5 × ULN or if creatinine \\> 1.5 × ULN then calculated creatinine clearance must be ≥ 60 mL\u002Fmin (using the Cockcroft-Gault formula)\n8. Women of childbearing potential must have a negative serum pregnancy test at screening.\n9. Participant can swallow tablets.\n10. Participant able to have MRI.\n11. Ability to understand and the willingness to personally sign the written IRB-approved informed consent document.\n12. Contraceptive use by men or women should be consistent with the standard that will be used at Stanford regarding the methods of contraception for those participating in clinical studies.\n\n    1. Male participants: Male participants are eligible to participate if they agree to the following during the treatment period and for at least 90 days after the last dose of study treatment:\n\n       • Refrain from donating or preserving sperm;\n\n       PLUS either:\n       * Be abstinent from sexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent; OR\n       * Must agree to use a male condom when having sexual intercourse with women of childbearing potential (WOCBP). An additional form of contraception as described in Appendix G should also be used by the female partner, if she is of childbearing potential.\n\n       Postmenopausal state (not of childbearing potential) is defined as no menses for 12 months without an alternative medical cause.\n    2. Female participants: A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:\n\n       * Is not of childbearing potential (not WOCBP). OR\n       * Is of childbearing potential but is abstinent or using 1 highly effective contraceptive method, as described in Appendix H during the treatment periodand for at least\n\n         1 week after the last dose of active study treatment. A second method of contraception is required if the participant is using hormonal contraception, as coadministration with nirogacestat may alter the plasma concentrations of hormonal contraceptives resulting reduced efficacy. Additionally, the participant agrees not to harvest or donate eggs (ova, oocytes) for the purpose of reproduction during the treatment period and for at least 6 months after the last dose of active study treatment. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study treatment.\n       * The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.\n\nExclusion Criteria:\n\n1. Participant previously received or is currently receiving therapy with GS inhibitors or anti-Notch antibody therapy.\n2. Participant is currently using any treatment for DT including tyrosine kinase inhibitors (TKIs), NSAIDS (chronic daily use - except as in inclusion criterion 4) or any investigational treatment 28 days (or 5 half-lives, whichever is longer) prior to the first dose of study treatment.\n3. Participant is currently using or anticipates using food or drugs that are known strong or moderate cytochrome P450 3A4 (CYP3A4) inhibitors, or strong CYP3a inducers within 14 days prior to the first dose of study treatment.\n4. Participant has known hypersensitivity to the active substance or to any of the excipients of nirogacestat.\n5. Participant with active or chronic infection at the time of informed consent and during the screening period.\n6. Participant has known malabsorption syndrome or preexisting gastrointestinal condition that may impair absorption of nirogacestat (e.g., gastric bypass, lap band, or other gastric procedures that would alter absorption); delivery of nirogacestat via nasogastric tube or gastrostomy tube is not allowed.\n7. History of other high-grade malignancy ≤ 2 years previous. Exceptions include prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen; adequately treated basal cell or squamous cell skin cancer; or adequately treated, with curative intent, cancer from which the subject is currently in complete remission per study Principal Investigator's (PI's) judgment. Specific situations can be discussed with study PI.\n8. Participant has experienced any of the following within 6 months of signing informed consent:\n\n   * Clinically significant cardiac disease (New York Heart Association Class III or IV);\n   * Myocardial infarction\n   * Severe \u002F unstable angina\n   * Coronary \u002F peripheral artery bypass graft\n   * Symptomatic congestive heart failure\n   * Cerebrovascular accident\n   * Transient ischemic attack\n   * Symptomatic pulmonary embolism\n9. Participant has congenital long QT syndrome.\n10. Participant has a history of additional risk factors for Torsades de pointes (TdP) (e.g., heart failure, hypokalemia, family history of long QT syndrome).\n11. Participant has current or chronic history of liver disease or known hepatic or biliary abnormalities (except for Gilbert's syndrome or asymptomatic gallstones).\n12. Participant is currently enrolled or was enrolled within 28 days of first dose of study treatment in another clinical study with any investigational drug or device.\n\nAll subject files must include supporting documentation to confirm subject eligibility. The method of confirmation can include, but is not limited to, laboratory test results, radiology test results, subject self-report, and medical record review.",{"count":134,"type":21},28,[79],"The primary purpose of this protocol is Systemic therapy with oral study agent, nirogacestat, followed by a single cryoablation procedure.",[27],[139,112,30],"Desmoid","2025-09-04",{"date":142,"type":40},"2025-09-08",{"date":144,"type":40},"2023-08-15",{"date":146,"type":21},"2028-02-01",{"name":148,"class":124},"Nam Bui",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":156,"sex":55,"minAge":17,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":94},"100543442","a-prospective-clinical-study-on-the-safety-and-efficacy-of-radiofrequency-ablation-for-the-treatment-of-patients-with-desmoid-tumors-100543442","NCT06355921","A Prospective Clinical Study on the Safety and Efficacy of Radiofrequency Ablation for the Treatment of Patients With Desmoid Tumors","RFAdesmoid","Inclusion Criteria:\n\n1. Patients with histologically verified diagnosis of dermoid tumor\n2. The presence of progressive, symptomatic or functionally significant DF.\n3. Written Informed consent to participate in the study\n4. Age from 18 to 75 years\n5. The functional status of the patient according to the ECOG 0-2 scale\n6. Normal renal function (estimated creatinine clearance 60 ml\u002Fmin);\n7. Normal level of bilirubin and liver enzymes (AST, ALT - no more than 3 norms);\n8. Left ventricular ejection fraction \\> 55%\n9. Satisfactory bone marrow function (hemoglobin level 9 g\u002Fdl, neutrophil count 1.5 thousand\u002Fml, platelet count \\< 100 thousand\u002Fml);\n\nExclusion Criteria:\n\n1. The inability to obtain informed consent to participate in the study\n2. Synchronous or metachronous cancer\n3. Clinically significant diseases of the cardiovascular system\n4. Clinically significant CNS diseases\n5. Previous grade 2 polyneuropathy and above\n6. Current infection or other severe or systemic disease that increases the risk of complications of therapy\n7. Pregnancy, lactation",true,"75 Years",{"count":159,"type":21},27,[107],"This is a prospective study on the safety and effectiveness of radiofrequency ablation in patients with desmoid tumors.\n\nIn the study group, all patients after radiofrequency ablation of the tumor after 1 month will be evaluated using MRI and CT studies and, if solid components of the tumor are detected, repeated surgical treatment is performed followed by active monitoring after 1 month.\n\nIn the absence of a solid component, the effect is estimated by the volume of the necrotic process and monitored in dynamics every 3 months.",[27,163,139],"Desmoid Fibromatosis","NOT_YET_RECRUITING","2024-04-03",{"date":167,"type":40},"2024-04-10",{"date":169,"type":21},"2024-04-01",{"date":171,"type":21},"2028-05-01",{"name":173,"class":124},"Blokhin's Russian Cancer Research Center"]